Specific Gal-1 inhibitor efficacy has been described in oral squamous cell carcinoma, thyroid carcinoma, HCC, ovarian carcinoma, breast carcinoma, or small cell lung carcinoma [21,22,52,87,93,94]. This evidence concerns the gene LGALS1 and breast carcinoma.